001007370 001__ 1007370
001007370 005__ 20230929112530.0
001007370 0247_ $$2doi$$a10.3390/biomedicines11040995
001007370 0247_ $$2Handle$$a2128/34445
001007370 0247_ $$2pmid$$a37189613
001007370 0247_ $$2WOS$$aWOS:000977211400001
001007370 037__ $$aFZJ-2023-02035
001007370 082__ $$a570
001007370 1001_ $$0P:(DE-Juel1)187451$$aWintz, Katharina$$b0$$ufzj
001007370 245__ $$aOral Treatment with d-RD2RD2 Impedes Early Disease Mechanisms in SOD1*G93A Transgenic Mice but Does Not Prolong Survival
001007370 260__ $$aBasel$$bMDPI$$c2023
001007370 3367_ $$2DRIVER$$aarticle
001007370 3367_ $$2DataCite$$aOutput Types/Journal article
001007370 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1684321715_27803
001007370 3367_ $$2BibTeX$$aARTICLE
001007370 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001007370 3367_ $$00$$2EndNote$$aJournal Article
001007370 520__ $$aAmyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting upper and lower motor neurons, thus, progressing to complete muscle loss until the patient dies from respiratory arrest. The disease is not curable, and patients die approximately 2–5 years after diagnosis. Studying the underlying disease mechanisms to get access to new treatment options is, therefore, essential for patients’ benefit. However, so far, only three drugs that alleviate the symptoms have been approved by the U.S. Food and Drug Administration (FDA). A new drug candidate for the treatment of ALS is the all-d-enantiomeric peptide RD2RD2. In this study, we investigated the therapeutic effect of RD2RD2 in two setups. First, we analyzed disease progression and survival in 7 week-old B6.Cg-Tg(SOD1*G93A)1Gur/J mice. Second, we confirmed the result of the survival analysis in the B6SJL-Tg(SOD1*G93A)1Gur/J mouse line. Shortly before disease onset, the mice were treated daily with an oral dose of 50 mg/kg body weight. Treatment with RD2RD2 led to a delayed disease onset and reduced motor phenotype as shown using the SHIRPA test, the splay reflex test, and the pole test, but did not affect survival. In conclusion, RD2RD2 has the ability to delay the onset of symptoms.
001007370 536__ $$0G:(DE-HGF)POF4-5244$$a5244 - Information Processing in Neuronal Networks (POF4-524)$$cPOF4-524$$fPOF IV$$x0
001007370 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001007370 7001_ $$0P:(DE-Juel1)164337$$aPost, Julia$$b1
001007370 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b2
001007370 7001_ $$0P:(DE-Juel1)132029$$aWillbold, Dieter$$b3
001007370 7001_ $$0P:(DE-Juel1)144347$$aWilluweit, Antje$$b4$$eCorresponding author
001007370 7001_ $$0P:(DE-Juel1)159137$$aKutzsche, Janine$$b5$$eCorresponding author
001007370 773__ $$0PERI:(DE-600)2720867-9$$a10.3390/biomedicines11040995$$gVol. 11, no. 4, p. 995 -$$n4$$p995 -$$tBiomedicines$$v11$$x2227-9059$$y2023
001007370 8564_ $$uhttps://juser.fz-juelich.de/record/1007370/files/biomedicines-11-00995.pdf$$yOpenAccess
001007370 8767_ $$d2023-05-10$$eAPC$$jZahlung erfolgt
001007370 909CO $$ooai:juser.fz-juelich.de:1007370$$pdnbdelivery$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire
001007370 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)187451$$aForschungszentrum Jülich$$b0$$kFZJ
001007370 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b2$$kFZJ
001007370 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132029$$aForschungszentrum Jülich$$b3$$kFZJ
001007370 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144347$$aForschungszentrum Jülich$$b4$$kFZJ
001007370 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159137$$aForschungszentrum Jülich$$b5$$kFZJ
001007370 9131_ $$0G:(DE-HGF)POF4-524$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5244$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vMolecular and Cellular Information Processing$$x0
001007370 9141_ $$y2023
001007370 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
001007370 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
001007370 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
001007370 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
001007370 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-03-30
001007370 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-03-30
001007370 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001007370 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-03-30
001007370 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-03-30
001007370 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001007370 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-03-30
001007370 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBIOMEDICINES : 2022$$d2023-08-29
001007370 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-29
001007370 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-29
001007370 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-29
001007370 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-07T16:28:21Z
001007370 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-07T16:28:21Z
001007370 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-07T16:28:21Z
001007370 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-29
001007370 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-29
001007370 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-29
001007370 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-29
001007370 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-29
001007370 9201_ $$0I:(DE-Juel1)IBI-7-20200312$$kIBI-7$$lStrukturbiochemie$$x0
001007370 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
001007370 980__ $$ajournal
001007370 980__ $$aVDB
001007370 980__ $$aUNRESTRICTED
001007370 980__ $$aI:(DE-Juel1)IBI-7-20200312
001007370 980__ $$aI:(DE-Juel1)INM-4-20090406
001007370 980__ $$aAPC
001007370 9801_ $$aAPC
001007370 9801_ $$aFullTexts